Given the augmented cell autophagy that emerged in cells under EGFR-TKI treatment, as many researchers demonstrated, we intended to kill gefitinib-resistant NSCLC cells via overwhelming autophagic turnover using the combination treatment of gefitinib and rapamycin. Here, EGFR is linked to non-small cell lung carcinoma.